Page last updated: 2024-08-24

emtricitabine and Vaginosis, Bacterial

emtricitabine has been researched along with Vaginosis, Bacterial in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Abdool Karim, Q; Abdool Karim, SS; Archary, D; Elsherbini, JA; Kwon, DS; Lewis, L; Mansoor, LE; Mazibuko-Motau, N; Mtshali, A; Mzobe, G; Ngcapu, S; Ntuli, L; San, JE; Sobia, P; Xu, J1
Baeten, JM; Balkus, JE; Bukusi, E; Celum, C; Cohen, CR; Donnell, D; Fiedler, T; Fredricks, DN; Heffron, R; Kiarie, J; Lingappa, J; McClelland, RS; Mugo, N; Munch, M1

Trials

1 trial(s) available for emtricitabine and Vaginosis, Bacterial

ArticleYear
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
    The lancet. HIV, 2017, Volume: 4, Issue:10

    Topics: Adult; Anti-HIV Agents; Dysbiosis; Emtricitabine; Female; Gardnerella vaginalis; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kenya; Microbiota; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda; Vagina; Vaginosis, Bacterial

2017

Other Studies

1 other study(ies) available for emtricitabine and Vaginosis, Bacterial

ArticleYear
Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women.
    Scientific reports, 2022, 09-28, Volume: 12, Issue:1

    Topics: Anti-Bacterial Agents; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Vagina; Vaginosis, Bacterial

2022